Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients
| dc.contributor.author | Şekuri C. | |
| dc.contributor.author | Çam F.S. | |
| dc.contributor.author | Tengiz I. | |
| dc.contributor.author | Ercan E. | |
| dc.contributor.author | Bayturan Ö. | |
| dc.contributor.author | Berdeli A. | |
| dc.date.accessioned | 2025-04-10T11:17:06Z | |
| dc.date.available | 2025-04-10T11:17:06Z | |
| dc.date.issued | 2006 | |
| dc.description.abstract | Objective: Platelet-activating factor (PAF) is a phospholipid with multiple actions that is involved in inflammatory diseases as well as in atherogenesis. It is inactivated by a plasma enzyme, PAF-acetylhydrolase (PAF-AH). Deficiency of this enzyme in plasma is caused by a missense mutation in the gene (G994T). The aim of this study was to investigate association of this mutation with premature coronary artery disease (CAD). Methods: One hundred and fifteen unrelated Turkish patients with a diagnosis of premature CAD and 128 unrelated healthy subjects were enrolled in this study. Genotyping was performed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results: The prevalence of the G994T mutation in the patients was 2.60 % (heterozygote), and 0 % in the controls. There was no significant difference in allele frequency and genotype distribution among the study groups. Conclusion: The G9943T mutation in the plasma PAF acetylhydrola se gene is not associated with premature CAD in Turkish subjects. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/52354 | |
| dc.title | Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients | |
| dc.type | Article |